CD22 MicroBeads, human

CD22 MicroBeads were developed for positive selection or depletion of human B cells from PBMCs, bone marrow, or single-cell suspensions from lymphoid tissues.

qualityAssuranceSatisfaction
guaranteed
more »

Related products for CD22 MicroBeads, human

Specifications for CD22 MicroBeads, human
Overview

CD22 MicroBeads were developed for positive selection or depletion of human B cells from PBMCs, bone marrow, or single-cell suspensions from lymphoid tissues.

Detailed product information
Background information

In peripheral blood, cell surface expression of the CD22 antigen is found on mature B cells, but is lost during terminal differentiation to plasma cells. In bone marrow, surface expression of CD22 can be detected from the pre-B cell stage on. Cytoplasmic expression of CD22 can also be found in late pro-B cells and early pre-B cells.

Downstream applications

The purified B cells may be used for cell biological studies, such as analysis of signal transduction2, mixed lymphocyte responses1, antigen presentation, or for molecular studies, e.g. PCR analysis3.

Columns

For positive selection: MS, LS, XS, or autoMACS® Columns. For depletion: LD, D, or autoMACS Columns.

Product data and images for CD22 MicroBeads, human
Figure 1

Separation of CD22+ cells from PBMCs using CD22 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD19-FITC.

Citations for CD22 MicroBeads, human
Publications
  1. Borson, N. D. et al. (2002) Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood 100: 4629-4639
  2. Butch, A. W. et al. (1999) Human follicular dendritic cells inhibit superantigen-induced T-cell proliferation by distinct mechanisms. Blood 94: 216-224
  3. Jacquot, S. et al. (2001) B cell co-receptors regulating T cell-dependent antibody production in common variable immunodeficiency: CD27 pathway defects identify subsets of severely immuno-compromised patients. Int. Immunol. 13: 871-876